karppaus.infon arkistoitu foorumi

Abstract
Aim
To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension.

Materials and Methods
STEP 1 (NCT03548935) randomized 1961 adults with a body mass index ≥ 30 kg/m2 (or ≥ 27 kg/m2 with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose escalation) or placebo, as an adjunct to lifestyle intervention. At week 68, treatments (including lifestyle intervention) were discontinued. An off-treatment extension assessed for a further year a representative subset of participants who had completed 68 weeks of treatment. This subset comprised all eligible participants from any site in Canada, Germany and the UK, and sites in the United States and Japan with the highest main phase recruitment. All analyses in the extension were exploratory.

Results
Extension analyses included 327 participants. From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4. percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120. Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.

Conclusions
One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.

So the GLP-1 agonists stimulate adipose hyperplasia meaning you develop lots of small adipocytes which are much better able to act as a sump for calories. There appears to be a shift of fatty acids out of pre-existing hypertrophied adipocytes, and out of ectopic fat deposition sites too, and in to these spanking new baby adipocytes.

– Minulle tämän määräsi lääkäri painonpudotukseen ja tulos oli kaksinkertainen painonnousu.

Lääkkeen avulla laihdutetut kilot palasivat lopulta takaisin korkojen kera.

– Kilot palasivat tuplana takaisin, hän sanoo podcastissa.

Hän kertoo tuoreessa Watch What Happens Live -ohjelman haastattelussa menneensä niin huonoon kuntoon, että siitä kärsi jo lapsikin:

Is it my imagination or is there a story-a-day on Ozempic?
Going on a ketogenic diet also makes "food noise" disappear for people, bc they're satiated by protein+fat, but bc there's no pharma $$ behind it, you'll see that story... not at all

– Viestitin siskolleni, ettei tämä enää ole tervettä. Nyt on niin huonot fiilikset, että pitää käydä lääkärissä ennen kuin menen junan alle, Takamaa sanoo.